Vivtex

Vivtex and AI Proteins enter strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases

18 January 2024 – Cambridge/Boston, MA, USA – Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing biotechnology company that utilises computational de novo protein design to create novel therapeutic miniproteins, today announced they have entered a strategic R&D collaboration...
790 Memorial Drive Suite 300 Cambridge, MA 02139, US